Century Therapeutics Stock In The News
| IPSC Stock | USD 0.56 0.01 1.82% |
Our overall analysis of Century Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Century Therapeutics. The specific impact of Century Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Century Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Century Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Century Therapeutics Backtesting and Century Therapeutics Hype Analysis. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Century and other traded companies coverage with news coverage. We help investors stay connected with Century headlines for the 22nd of March to make an informed investment decision based on correlating the impacts of news items on Century Stock performance. Please note that trading solely based on the Century Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Century |
Century Therapeutics Today Top News and Investor Outlook
Century Therapeutics Past News Timeline
Century Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Century earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Century Therapeutics that are available to investors today. That information is available publicly through Century media outlets and privately through word of mouth or via Century internal channels. However, regardless of the origin, that massive amount of Century data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Century Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Century Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Century Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Century Therapeutics alpha.
Century Largest EPS Surprises
Earnings surprises can significantly impact Century Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.5 | -0.45 | 0.05 | 10 | ||
2022-11-10 | 2022-09-30 | -0.59 | -0.53 | 0.06 | 10 | ||
2024-11-05 | 2024-09-30 | -0.45 | -0.37 | 0.08 | 17 | ||
2021-11-10 | 2021-09-30 | -0.4 | -0.48 | -0.08 | 20 | ||
2024-12-31 | 2024-12-31 | -0.4375 | -0.3542 | 0.0833 | 19 | ||
2024-03-14 | 2023-12-31 | -0.55 | -0.65 | -0.1 | 18 |
Century Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Century Therapeutics Stock. Current markets are strongly bearish. About 75% of major world exchanges and indexes are down. See today's market update for more information.
21st of March 2025
Century Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags at simplywall.st
19th of March 2025
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update at gurufocus.com
11th of March 2025
Acquisition by Carr Douglas of 95625 shares of Century Therapeutics at 0.601 subject to Ru... at zacks.com
28th of February 2025
Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency -February 28, 2025 at... at news.google.com
19th of February 2025
Century Therapeutics Advancing Cell Therapy Innovation Amid Market Dynamics at kalkinemedia.com
12th of February 2025
Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs at finance.yahoo.com
3rd of February 2025
Disposition of 351 shares by Carr Douglas of Century Therapeutics at 0.78 subject to Rule ... at MacroaxisInsider
22nd of January 2025
Century Therapeutics, Inc. Given Average Rating of Buy by Brokerages at thelincolnianonline.com
21st of January 2025
Century Therapeutics Announces Investigator-Initiated Phase 12 Trial of its iPSC-derived i... at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Century Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Century Therapeutics' short interest history, or implied volatility extrapolated from Century Therapeutics options trading.
Check out Century Therapeutics Backtesting and Century Therapeutics Hype Analysis. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.62) | Revenue Per Share | Quarterly Revenue Growth 14.571 | Return On Assets | Return On Equity |
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.